Navigation Links
BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
Date:9/3/2013

JERUSALEM, Sept. 3, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the 15th Annual Rodman & Renshaw Global Investment Conference at the Millennium Broadway Hotel in New York.

(Logo: http://photos.prnewswire.com/prnh/20130730/630769)

The BioLineRx presentation is scheduled to start at 11:40 a.m. EDT on Tuesday, September 10, 2013. A live audio webcast of the presentation will be available online at BioLineRx's investor web page. An archive of the event will also be available for those unable to listen live.

In addition, any investors attending the conference that wish to meet with Dr. Savitsky and Mr. Serlin for a one-on-one meeting should contact Lily Khaykina at LK@rodm.com.

About BioLineRx
BioLineRx is a publicly-traded biopharmaceutical development company dedicated to building a portfolio of products for unmet medical needs, as well as those with advantages over currently available therapies. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx's current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Ikaria Inc. and is in the midst of a pivotal CE-Mark registration trial; BL-5010 for non-surgical removal of skin lesions, which is expected to commence a pivotal CE-mark registration trial in late 2013; BL-8040 for treating acute myeloid leukemia (AML) and other hematological cancers, which is in the midst of a Phase 2 study; and BL-7010 for celiac disease, which is expected to commence a Phase 1/2 study in late 2013.

For more information on BioLineRx, please visit www.biolinerx.com or download the investor relations mobile device app, which allows users access to the Company's SEC documents, press releases, and events. BioLineRx's IR app is available on the iTunes App Store as well as the Google Play Store.

Contact:
KCSA Strategic Communications
Garth Russell / Todd Fromer
+1 212-896-1250 / +1 212-896-1250
grussell@kcsa.com / tfromer@kcsa.com

or

Tsipi Haitovsky
Public Relations
+972-3-6240871
tsipih@netvision.net.il


'/>"/>
SOURCE BioLineRx
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 for Obtaining Stem Cells
2. BioLineRx to Present at 15th International Celiac Disease Symposium
3. BioLineRx to Present at 2013 Stifel Nicolaus Healthcare Conference In Boston
4. BioLineRx Appoints B. J. Bormann to Board of Directors
5. BioLineRx Reports Second Quarter 2013 Results
6. BioLineRx Announces Publication of Positive Pre-Clinical Results for BL-8040 in Treatment of Thrombocytopenia
7. DelMar Pharmaceuticals To Present At The 15th Annual Rodman & Renshaw Global Investment Conference
8. PharmAthene to Present at Rodman & Renshaw Annual Global Investment Conference
9. Inovio Pharmaceuticals to Present at Upcoming Investor Conferences
10. Amgen And Cytokinetics Announce The First Presentation Of Data From Phase 2 ATOMIC-AHF Study Of Omecamtiv Mecarbil
11. AcelRx Pharmaceuticals to Present at the Stifel Healthcare Conference 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Ariz. , Feb. 8, 2016  Ventana ... announced that hundreds of the world,s top oncologists, ... gather at the 12 th annual Tucson ... findings, evolving theories and new outcomes in cancer ... and patients, lives. Thomas Grogan , ...
(Date:2/8/2016)... , Feb. 8, 2016 ... the "Global Skin Protective Equipment Market 2016-2020" ... --> http://www.researchandmarkets.com/research/fqx6nz/global_skin ) has announced the addition ... 2016-2020" report to their offering. ... ) has announced the addition of the ...
(Date:2/8/2016)... -- A research team led by St. Jude Children,s ... the abnormal breakage and rearrangement of chromosomes in white ... lymphoblastic leukemia (ALL). Such leukemias are cancers of white ... immature cells, called lymphoblasts. --> ... the type called "Ph-like ALL" will aid in designing ...
Breaking Medicine Technology:
(Date:2/8/2016)... IN (PRWEB) , ... February 08, 2016 , ... ... the Indianapolis, IN metro area, has selected the latest beneficiary of their ongoing ... organization dedicated to preventing bullying in area schools. Donations are now being accepted ...
(Date:2/8/2016)... ... 2016 , ... Remember the old saying “rub some dirt on it”? Perhaps ... of “Calcium Bentonite Clay” the health benefits of integrating clay into a daily diet ... , A former motivational speaker, Perry A~ has since dedicated her life to learning ...
(Date:2/8/2016)... ... February 08, 2016 , ... GrassrootsHealth published data ... of type 2 diabetes in the GrassrootsHealth cohort with substantially higher vitamin D ... change in public health,” states Carole Baggerly, Director of GrassrootsHealth, “the safety ...
(Date:2/8/2016)... ... 2016 , ... Guruji Mahendra Kumar Trivedi is offering 3 days of accelerated ... his birthday on February 10th. During this time, people can achieve better health, ... 250,000 people from over 40 different countries as an “ordinary man with an extraordinary ...
(Date:2/7/2016)... ... February 07, 2016 , ... Women's Excellence staff, in all ... Day. National Wear Red Day is the first Friday each February and a ... stroke cause 1 in 3 deaths among women each year – more than all ...
Breaking Medicine News(10 mins):